2.29
+0.0819(+3.71%)
Currency In USD
| Previous Close | 2.21 |
| Open | 2.24 |
| Day High | 2.31 |
| Day Low | 2.2 |
| 52-Week High | 5.33 |
| 52-Week Low | 0.89 |
| Volume | 47,393 |
| Average Volume | 231,033 |
| Market Cap | 60.79M |
| PE | -2.1 |
| EPS | -1.09 |
| Moving Average 50 Days | 1.94 |
| Moving Average 200 Days | 1.89 |
| Change | 0.08 |
If you invested $1000 in Gain Therapeutics, Inc. (GANX) since IPO date, it would be worth $187.86 as of February 05, 2025 at a share price of $2.292. Whereas If you bought $1000 worth of Gain Therapeutics, Inc. (GANX) shares 3 years ago, it would be worth $503.71 as of February 05, 2025 at a share price of $2.292.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Gain Therapeutics To Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
2 hours ago
BETHESDA, Md., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule the
Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287
GlobeNewswire Inc.
Jan 08, 2025 1:00 PM GMT
BETHESDA, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule the
Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director
GlobeNewswire Inc.
Jan 07, 2025 12:00 PM GMT
Gene Mack Has Served As CFO Since April 2024 And Interim CEO Since June 2024 Gianluca Fuggetta Will Assume The Role Of Senior Vice President, Finance BETHESDA, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, o